Phaseline

Companies › CNBG-Virogin Biotech (Shanghai)

CNBG-Virogin Biotech (Shanghai): clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VG161
Recombinant oncolytic HSV-1 expressing human IL-12 and IL-15 fused to PDL1B
–Phase 2Sarcoma; Advanced Intrahepatic Cholangiocarcinoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06126510VG161Phase 2SarcomaOncologyJul 2025
NCT06746480VG161Phase 2Advanced Intrahepatic CholangiocarcinomaOncologySep 2025

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Stella Pharma Dendreon Hangzhou Converd Abscint NV/SA Beijing Gene Key Life Technology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.